Skip to main content
Erschienen in: Pituitary 2/2019

07.02.2019

Clinical score system in the treatment of Cushing’s disease: failure to identify discriminative variables from the German Cushing’s Registry

verfasst von: Mareike R. Stieg, Matthias K. Auer, Christina Berr, Julia Fazel, Martin Reincke, Stephanie Zopp, Alexander Yassouridis, Günter K. Stalla

Erschienen in: Pituitary | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop a multidimensional and integrated clinical scoring instrument, that encompasses, summarizes and weights appropriately the desired clinical benefits of a treatment for Cushing’s disease (CD).

Methods

A panel of 42 variables potentially relevant to the clinical course of CD was predefined by endocrinology experts taking into account relevant literature. Variables as well as biochemical disease activity assessed as urinary free cortisol (UFC) levels were evaluated at baseline and at least after 12 months in patients treated between 2012 and 2016 in two Munich-based academic centres of the German Cushing’s Registry. The primary endpoint was the identification of variables whose changes from baseline to follow-up visit(s) could characterize well biochemical cured from not cured patients after 12 months.

Results

Ninety nine patients with at least two consecutive visits were enrolled. Biochemical data were available for 138 visit-pairs among which UFC was not controlled in 48 (34.8%) and controlled in 90 (65.2%) first visits. In 41 (29.7%) consecutive visits (visit-pairs) changes in biochemical activity categories was observed between visits; concretely: in 17 (12.3%) consecutive visits changing from previously controlled to not controlled, and in 24 (17.4%) from uncontrolled to controlled biochemical activity. Multivariate statistical analyses (especially analyses of variance) based on data of the 138 visit-pairs were performed in order to proof possible effects of biochemical activity on clinical benefits. However, in none of the considered 42 variables corresponding to quality of life-dimensions, laboratory, anthropometric, musculo-skeletal or other clinical areas any statistically significant differences between different categories of biochemical activity were observed.

Conclusion

It was not possible to provide clinical key parameters in our population of patients with CD discriminating biochemical cured from non-cured patients and to construct a clinical scoring system reflecting clinical treatment benefits.
Literatur
1.
Zurück zum Zitat Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791CrossRef Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791CrossRef
2.
Zurück zum Zitat Berr CM, Ritzel K, Osswald A, Schopohl J, Beuschlein F, Reincke M (2014) Time from symptoms to diagnosis in Cushing’s syndrome: results of the German Cushing Registry in Munich. Exp Clin Endocrinol Diabetes 122:LB18CrossRef Berr CM, Ritzel K, Osswald A, Schopohl J, Beuschlein F, Reincke M (2014) Time from symptoms to diagnosis in Cushing’s syndrome: results of the German Cushing Registry in Munich. Exp Clin Endocrinol Diabetes 122:LB18CrossRef
3.
Zurück zum Zitat Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165(3):383–392CrossRef Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165(3):383–392CrossRef
4.
Zurück zum Zitat Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632–642CrossRef Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632–642CrossRef
5.
Zurück zum Zitat Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
6.
Zurück zum Zitat Stewart PM, Sherlock M (2012) Mortality and pituitary disease. Ann Endocrinol (Paris) 73(2):81–82CrossRef Stewart PM, Sherlock M (2012) Mortality and pituitary disease. Ann Endocrinol (Paris) 73(2):81–82CrossRef
7.
Zurück zum Zitat Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N (2013) Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715–723CrossRef Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N (2013) Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715–723CrossRef
8.
Zurück zum Zitat Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23(3):278–282CrossRef Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23(3):278–282CrossRef
9.
Zurück zum Zitat Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18(2):188–194CrossRef Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18(2):188–194CrossRef
10.
Zurück zum Zitat Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 34(2):327–339 viiiCrossRef Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 34(2):327–339 viiiCrossRef
11.
Zurück zum Zitat Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRef Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRef
12.
Zurück zum Zitat Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRef Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRef
13.
Zurück zum Zitat van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143–R149CrossRef van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143–R149CrossRef
14.
Zurück zum Zitat Sonino N, Fava GA (1998) Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 67(3):140–146CrossRef Sonino N, Fava GA (1998) Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 67(3):140–146CrossRef
15.
Zurück zum Zitat Santos A, Resmini E, Martinez MA, Marti C, Ybarra J, Webb SM (2009) Quality of life in patients with pituitary tumors. Curr Opin Endocrinol Diabetes Obes 16(4):299–303CrossRef Santos A, Resmini E, Martinez MA, Marti C, Ybarra J, Webb SM (2009) Quality of life in patients with pituitary tumors. Curr Opin Endocrinol Diabetes Obes 16(4):299–303CrossRef
16.
Zurück zum Zitat Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630CrossRef Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630CrossRef
17.
Zurück zum Zitat Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36(4):385–486CrossRef Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36(4):385–486CrossRef
18.
Zurück zum Zitat Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C (2014) Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80(4):562–569CrossRef Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C (2014) Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80(4):562–569CrossRef
19.
Zurück zum Zitat Sundaram NK, Carluccio A, Geer EB (2014) Characterization of persistent and recurrent Cushing’s disease. Pituitary 17(4):381–391CrossRef Sundaram NK, Carluccio A, Geer EB (2014) Characterization of persistent and recurrent Cushing’s disease. Pituitary 17(4):381–391CrossRef
20.
Zurück zum Zitat McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef
21.
Zurück zum Zitat Nugent CA, Warner HR, Dunn JT, Tyler FH (1964) Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 24:621–627CrossRef Nugent CA, Warner HR, Dunn JT, Tyler FH (1964) Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 24:621–627CrossRef
22.
Zurück zum Zitat Castinetti F, Morange I, Conte-Devolx B, Brue T (2012) Cushing’s disease. Orphanet J Rare Dis 7:41CrossRef Castinetti F, Morange I, Conte-Devolx B, Brue T (2012) Cushing’s disease. Orphanet J Rare Dis 7:41CrossRef
23.
Zurück zum Zitat Nieman LK (2015) Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33–M38CrossRef Nieman LK (2015) Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33–M38CrossRef
24.
Zurück zum Zitat Pereira AM, Tiemensma J, Romijn JA (2010) Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 92(S1):65–70CrossRef Pereira AM, Tiemensma J, Romijn JA (2010) Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 92(S1):65–70CrossRef
25.
Zurück zum Zitat Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI (2016) SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary 19(1):39–49CrossRef Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI (2016) SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary 19(1):39–49CrossRef
26.
Zurück zum Zitat van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jørgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692–701CrossRef van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jørgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692–701CrossRef
Metadaten
Titel
Clinical score system in the treatment of Cushing’s disease: failure to identify discriminative variables from the German Cushing’s Registry
verfasst von
Mareike R. Stieg
Matthias K. Auer
Christina Berr
Julia Fazel
Martin Reincke
Stephanie Zopp
Alexander Yassouridis
Günter K. Stalla
Publikationsdatum
07.02.2019
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 2/2019
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-00942-2

Weitere Artikel der Ausgabe 2/2019

Pituitary 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.